CIDEB Antibody

What is CIDEB and why is it important in research?

CIDEB (Cell death-inducing DFFA-like effector b) is an ER and lipid droplet-associated protein primarily expressed in the liver that participates in lipid metabolism by regulating lipid droplet fusion and VLDL lipidation. Unlike other CIDE family members (CIDEA highly expressed in brown adipose tissue and CIDEC in white/brown adipose tissue), CIDEB is more abundant in liver, kidney, small intestine, and colon .

CIDEB has become important in research due to its roles in:

• Lipid metabolism and storage

• Sterol-regulated ER export of SREBP/SCAP

• Hepatitis C virus (HCV) entry into hepatocytes

• Potential involvement in apoptotic processes

The multifunctional nature of CIDEB makes antibodies against this protein crucial tools for researchers investigating metabolic disorders, viral infections, and cell death pathways.

Based on manufacturer recommendations, CIDEB antibodies should be stored at -20°C where they remain stable for one year after shipment . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For long-term storage, aliquoting is generally unnecessary for -20°C storage, though some smaller preparations (20µl sizes) may contain 0.1% BSA .

To avoid reduced activity:

• Minimize freeze/thaw cycles

• Keep at recommended temperature (-20°C)

• Work with aliquots when frequent use is required

• Follow manufacturer's specific storage recommendations, as formulations may vary slightly

How should I determine the optimal dilution for my CIDEB antibody experiment?

The optimal dilution for CIDEB antibody applications varies based on:

• The specific antibody preparation

• The application being performed

• The sample type and protein expression level

Methodological approach for optimization:

• Start with the manufacturer's recommended dilution range:

  • For WB: Begin with 1:1000 (typically ranges from 1:500-1:3000)

  • For IHC: Begin with 1:100 (typically ranges from 1:50-1:500)

• Perform a dilution series experiment:

  • Create a series of 3-5 dilutions within and slightly beyond the recommended range

  • Include appropriate positive controls (HepG2 cells for WB, mouse liver tissue for IHC)

  • Evaluate signal-to-noise ratio at each dilution

• Refine based on specific conditions:

  • Adjust based on expression level in your specific samples

  • Consider detection method sensitivity (chemiluminescence, fluorescence)

  • Include sample-dependent adjustments as noted in technical support documentation

A well-designed dilution optimization experiment saves antibody and prevents false negative results from insufficient antibody concentration or high background from excess antibody.

What are the most effective positive controls for validating CIDEB antibody specificity?

Selecting appropriate positive controls is crucial for validating CIDEB antibody specificity:

Cellular/Tissue Controls:

• High expression: HepG2 cells, L02 cells (human hepatic cell lines)

• Tissue samples: Mouse liver tissue (consistently shows high CIDEB expression)

• Additional validated samples: COLO205 cells (colorectal adenocarcinoma)

Verification Methods:

• Peptide blocking experiments: Pre-incubate antibody with immunogenic peptide (several commercial CIDEB antibodies offer matching blocking peptides, e.g., PEP-0443, PEP-0035)

• CIDEB knockdown validation: Compare signal between normal and CIDEB-knockdown samples (using siRNA targeting sequences such as 5′-AAA GUA CUC AGG GAG CUC CUU-3′)

• CIDEB knockout verification: If available, TALEN-generated CIDEB knockout cells provide definitive negative controls

For the most rigorous validation, implement a multi-approach strategy combining different control methods to confirm specificity across your experimental conditions.

How can CIDEB antibodies be used to investigate lipid metabolism pathways?

CIDEB plays critical roles in lipid metabolism, making CIDEB antibodies valuable tools for investigating these pathways:

Experimental Approaches:

• Co-localization studies:

  • Use CIDEB antibodies in combination with lipid droplet stains (e.g., BODIPY 493/503)

  • Perform dual immunofluorescence with other lipid metabolism proteins (e.g., SREBP, SCAP)

  • Quantify co-localization coefficients under different metabolic conditions

• Protein-protein interaction analysis:

  • Immunoprecipitate CIDEB using validated antibodies to identify binding partners

  • Co-immunoprecipitation experiments have revealed CIDEB interaction with SCAP but not SREBP-1/2 or Insig

  • Sterol-dependent interaction studies show that CIDEB interacts with SCAP only in the absence of sterols, with interaction disrupted by 25-HC

• CIDEB-mediated lipid regulatory pathway investigation:

  • Combined CIDEB antibody detection with genetic manipulation:

  Experimental Approach	Effect on Lipid Metabolism	Detection Method	Reference
  CIDEB overexpression	↑ TAG content, ↑ lipid droplet formation	Western blot with CIDEB antibody + BODIPY staining
  CIDEB knockdown	↓ TAG content, ↓ lipid droplet formation	Western blot verification of knockdown efficacy
  CIDEB knockout	↓ SREBP-1N levels (~60%), ↓ SREBP-1N and SREBP-2N (~70%)	Western blot analysis of nuclear fractions

What modifications can improve CIDEB antibody performance in challenging samples?

When working with difficult samples or tissues with low CIDEB expression, several methodological modifications can enhance detection:

• Signal amplification strategies:

  • Employ biotin-streptavidin amplification systems

  • Use tyramide signal amplification (TSA) for IHC/IF applications

  • Consider more sensitive chemiluminescent substrates for WB

• Antigen retrieval optimization:

  • For IHC applications, compare both recommended methods:

    • TE buffer pH 9.0 (primary recommendation)

    • Citrate buffer pH 6.0 (alternative method)

  • Extended retrieval times (15-20 minutes) may improve detection in fixed tissues

• Sample preparation refinements:

  • For liver samples (high CIDEB expression), minimize lipid interference:

    • Include lipid extraction steps before protein analysis

    • Add additional detergents (0.1% SDS or 1% Triton X-100) to extraction buffers

  • For WB applications:

    • Load higher protein amounts (40-50μg versus standard 25μg)

    • Extend primary antibody incubation to overnight at 4°C

• Specialized detection methods:

  • For co-localization studies, super-resolution microscopy combined with CIDEB antibodies provides superior detection of CIDEB localization at lipid droplet-ER contact sites

How can CIDEB antibodies be used to study HCV infection mechanisms?

CIDEB has been identified as an essential cofactor for HCV entry into hepatocytes . CIDEB antibodies can be deployed in multiple experimental approaches to investigate this process:

• Infection step analysis using CIDEB antibodies:

  • CIDEB inhibition affects HCV at a post-attachment stage but before RNA translation

  • Specifically, CIDEB functions at the membrane fusion step required for viral RNA to escape endocytic vesicles

• Time-course experiments:

  • CIDEB knockdown affects HCV infection between 12-16 hours post-infection

  • Use CIDEB antibodies to track protein expression/localization changes during this critical window

• Virus-host membrane fusion assay methodology:

  • Label HCVcc particles with DiD (a self-quenching lipophilic dye)

  • Compare fusion efficiency between control and CIDEB knockdown cells

  • CIDEB knockdown reduces fusion puncta by >70% compared to control cells

  • Verify knockdown efficacy using CIDEB antibodies via Western blot

• Comparison with other viral infections:

  • CIDEB knockout cells show complete inhibition of HCV infection

  • In contrast, neither VSV nor WNV infection is significantly inhibited in these cells

  • CIDEB antibodies can confirm knockout efficacy in these comparative studies

This research application demonstrates how CIDEB antibodies can be instrumental in elucidating host-pathogen interactions at the molecular level.

How do I resolve discrepancies in CIDEB antibody detection between different cell types?

Researchers may encounter variations in CIDEB detection between different cell types or tissues. These discrepancies can provide valuable insights when properly analyzed:

• Expression level differences:

  • CIDEB is primarily expressed in liver, with lower expression in kidney, small intestine, and colon

  • Expected detection hierarchy: hepatocytes > intestinal cells > other cell types

  • Validation strategy: Use quantitative Western blot with recombinant CIDEB standards to calibrate expression levels

• Isoform detection variability:

  • Antibody epitope location affects which CIDEB isoforms are detected

  • Compare antibodies targeting different regions:

    • N-terminal region (AA 3-110)

    • Central region (AA 80-160)

    • C-terminal region

  • Multiple antibody approach can reveal tissue-specific isoform expression patterns

• Post-translational modification interference:

  • Phosphorylation or other modifications may mask epitopes in certain cell types

  • Methodological solution: Compare native versus denatured samples

  • Include phosphatase treatment controls to determine if modifications affect detection

• Cross-reactivity analysis:

  • CIDE family homology can cause cross-reactivity (CIDEA, CIDEB, CIDEC)

  • Validate using:

    • Overexpression systems with tagged constructs

    • Knockout/knockdown controls for each family member

    • Peptide competition assays with specific immunogenic peptides

A systematic approach to resolving these discrepancies not only improves experimental reliability but often reveals biologically significant insights about CIDEB regulation in different cellular contexts.

What are the optimal quantification methods for CIDEB using antibody-based techniques?

For accurate quantification of CIDEB using antibody-based techniques, consider these methodological approaches:

• Western blot quantification:

  • Use recombinant CIDEB protein standards (5-100 ng range) to generate standard curves

  • Include loading controls appropriate for your experimental conditions:

    • β-actin for general cell lysates

    • Calnexin for ER-enriched fractions (where CIDEB often localizes)

  • Employ fluorescent secondary antibodies rather than chemiluminescence for more accurate linear quantification

  • Validate signal linearity across your expected concentration range

• ELISA development for CIDEB quantification:

  • Sandwich ELISA approach using two antibodies targeting different CIDEB epitopes:

    • Capture antibody: Target conserved, accessible epitope (e.g., N-terminal region)

    • Detection antibody: Target distinct epitope (e.g., C-terminal region)

  • Optimize blocking conditions (5% BSA or 5% non-fat milk typically effective)

  • Standard dilution series creation: 0.1-10 ng/mL range typically appropriate

• Subcellular quantification strategies:

  • For accurate measurement of CIDEB distribution between ER and lipid droplets:

    • Perform subcellular fractionation with ultracentrifugation

    • Validate fraction purity with markers (e.g., calnexin for ER, PLIN2 for lipid droplets)

    • Normalize CIDEB signal to fraction-specific markers rather than total protein

• Image-based quantification:

  • For quantifying CIDEB localization changes:

    • Use fixed exposure settings across all experimental conditions

    • Measure colocalization with organelle markers (Pearson's correlation coefficient)

    • Employ automated image analysis software with consistent thresholding

How can I develop a multiplexed immunoassay involving CIDEB antibodies?

Developing multiplexed assays that include CIDEB antibodies requires careful planning and validation:

• Antibody compatibility assessment:

  • Test CIDEB antibody with potential multiplex partners for:

    • Cross-reactivity (especially with other CIDE family proteins)

    • Compatible incubation conditions (buffer, temperature, time)

  • Use sequential probing with complete stripping between antibodies to validate specificity

• Multiplex fluorescent immunostaining protocol development:

  • Use spectral separation strategy:

    • CIDEB detection: Rabbit polyclonal + Anti-rabbit secondary (e.g., Alexa 488)

    • Partner proteins: Select antibodies from different host species (mouse, goat)

    • Recommended partners for lipid metabolism studies: SREBP-1, SCAP, Insig

  • Include single-stain controls for spectral bleed-through correction

  • Employ nuclear counterstain (DAPI) for cell identification

• Multiplex Western blot optimization:

  • Size-based separation strategy:

    • CIDEB: ~28 kDa

    • Select partner proteins with clearly different molecular weights

    • Example compatible multiplex panel:

  Protein	Molecular Weight	Host Species	Recommended Dilution
  CIDEB	28 kDa	Rabbit	1:1000
  SREBP-1	125 kDa (precursor); 68 kDa (nuclear)	Mouse	1:500
  Calnexin	90 kDa	Goat	1:2000
  ACACA	265 kDa	Rabbit	1:1000

  • Use fluorescent secondary antibodies with different emission spectra

  • Include complete optimization of blocking conditions to minimize background

• Bead-based multiplex assay development:

  • Conjugate CIDEB antibody to beads with unique spectral properties

  • Optimize antibody coupling concentration (typically 5-10 μg per 1×10^6 beads)

  • Include BSA-conjugated control beads to establish baseline signals

  • Validate with recombinant CIDEB protein and lysates from CIDEB-knockout cells

What are the most common issues with CIDEB antibody experiments and how can they be resolved?

Researchers working with CIDEB antibodies may encounter several common challenges:

• High background in Western blots:

  • Possible causes:

    • Excessive antibody concentration

    • Insufficient blocking

    • Sample contamination

  • Solutions:

    • Further dilute primary antibody (try 1:2000-1:3000 for WB)

    • Increase blocking time (2h at room temperature) or concentration (5% milk/BSA)

    • Add 0.1% Tween-20 to wash buffers and increase washing frequency

    • Consider using a different blocking agent (switch between milk and BSA)

• Weak or no signal in IHC applications:

  • Possible causes:

    • Inadequate antigen retrieval

    • Fixation artifacts

    • Low CIDEB expression in sample

  • Solutions:

    • Try both recommended antigen retrieval methods (TE buffer pH 9.0 and citrate buffer pH 6.0)

    • Extend antigen retrieval time (15-20 minutes)

    • Increase antibody concentration (try 1:50 dilution)

    • Include positive control tissues known to express CIDEB (mouse liver)

    • Extend primary antibody incubation (overnight at 4°C)

• Multiple bands or unexpected molecular weight:

  • Possible causes:

    • Cross-reactivity with other CIDE family proteins

    • Post-translational modifications

    • Degradation products

  • Solutions:

    • Validate with blocking peptide competition

    • Include samples from CIDEB knockout or knockdown models

    • Use fresh samples and add complete protease inhibitor cocktails

    • Compare band patterns with different CIDEB antibodies targeting distinct epitopes

• Poor reproducibility between experiments:

  • Possible causes:

    • Antibody degradation

    • Variability in sample preparation

    • Inconsistent experimental conditions

  • Solutions:

    • Aliquot antibodies to minimize freeze-thaw cycles

    • Standardize lysate preparation protocols

    • Include internal control samples across experiments

    • Document detailed experimental conditions including incubation times and temperatures

How can CIDEB antibody performance be validated in experiments investigating novel functions of CIDEB?

When using CIDEB antibodies to explore novel functions or contexts, rigorous validation is essential:

• Genetic validation approaches:

  • Generate CIDEB knockdown controls:

    • Use validated siRNA sequences (e.g., 5′-AAA GUA CUC AGG GAG CUC CUU-3′)

    • Create shRNA stable knockdown cell lines for long-term studies

  • For definitive validation, use CIDEB knockout models:

    • TALEN-based CIDEB knockout has been successfully implemented

    • CRISPR/Cas9 targeting exon 3 of CIDEB is recommended

• Rescue experiment design:

  • Express shRNA-resistant CIDEB cDNA containing silent mutations:

    • Example modified sequence: 5′-AAA GTc CTg cGc GAa CTC CTT-3′ (lowercase letters represent silent mutations)

  • Verify rescue at both protein level (using CIDEB antibody) and functional level

• Cross-species validation:

  • CIDEB antibodies have validated reactivity across species:

    • Human, mouse, and rat reactivity is confirmed for many commercial antibodies

    • Compare CIDEB detection patterns across species to confirm evolutionary conservation

    • Differences in detection may reveal species-specific functions

• Novel interaction validation framework:

  • For newly identified CIDEB-protein interactions:

    • Perform reciprocal co-immunoprecipitations with both CIDEB antibody and partner protein antibody

    • Include negative controls (IgG, unrelated protein)

    • Confirm with orthogonal methods (proximity ligation assay, FRET)

    • Demonstrate functional relevance through activity assays